UBIAD1 and prostate carcinoma: TERE1/UBIAD1 overexpression inhibits the growth of TCC cell lines and prostate cancer cell lines, although no UBIAD1 mutations have been identified in individuals with TCC, suggesting that UBIAD1 synthesizes anti-tumour proliferating metabolites other than MK-4 or interacts directly with anti-cancer modulators [17]–[20].